

Paul R Fortin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5878644/publications.pdf>

Version: 2024-02-01

169
papers

14,559
citations

41627

51
h-index

23173

116
g-index

172
all docs

172
docs citations

172
times ranked

15626
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring the Impact of <sc>MyLupusGuide</sc> in Canada: Results of a Randomized Controlled Study. <i>Arthritis Care and Research</i> , 2023, 75, 529-539.	1.5	4
2	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
3	Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision-Making in Systemic Lupus Erythematosus Treatment?. <i>Arthritis Care and Research</i> , 2022, 74, 1070-1078.	1.5	10
4	Challenges of Perceived <sc>Self-Management</sc> in Lupus. <i>Arthritis Care and Research</i> , 2022, 74, 1113-1121.	1.5	8
5	Identification of Mitofusin 1 and Complement Component 1q Subcomponent Binding Protein as Mitochondrial Targets in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1193-1203.	2.9	13
6	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42
7	The Purinergic Receptor P2X4 Promotes Th17 Activation and the Development of Arthritis. <i>Journal of Immunology</i> , 2022, 208, 1115-1127.	0.4	7
8	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
9	Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematosus lupus. <i>Lupus Science and Medicine</i> , 2022, 9, e000605.	1.1	5
10	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€Registryâ€™™). <i>Lupus Science and Medicine</i> , 2022, 9, e000633.	1.1	9
11	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	1.5	13
12	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	1.5	22
13	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110314.	1.2	9
14	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
15	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 29.	1.6	27
16	Platelets release mitochondrial antigens in systemic lupus erythematosus. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	59
17	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
18	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	2.9	7

#	ARTICLE	IF	CITATIONS
19	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
20	Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study. BMC Rheumatology, 2021, 5, 52.	0.6	1
21	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31
22	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
23	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23
24	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
25	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27
26	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
27	Development and Acceptability of a Patient Decision Aid for Pain Management in Juvenile Idiopathic Arthritis: The JIA Option Map. Patient, 2020, 13, 719-728.	1.1	5
28	IgGâ€¦aggregates rapidly upregulate FcÎ³RI expression at the surface of human neutrophils in a FcÎ³RIIâ€¦dependent fashion: A crucial role for FcÎ³RI in the generation of reactive oxygen species. FASEB Journal, 2020, 34, 15208-15221.	0.2	5
29	FcÎ³RIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. Blood, 2020, 136, 2933-2945.	0.6	25
30	Pilot study of anti-mitochondrial antibodies in antiphospholipid syndrome. Lupus, 2020, 29, 1623-1629.	0.8	5
31	P98â€¦Neutrophils in lupus: a new phenotype. , 2020, , .		0
32	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€¦FI). Arthritis Care and Research, 2020, , .	1.5	9
33	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and metaâ€¦analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2274-2286.	1.9	24
34	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). Arthritis Research and Therapy, 2020, 22, 132.	1.6	5
35	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
36	Platelets Disseminate Extracellular Vesicles in Lymph in Rheumatoid Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 929-942.	1.1	40

#	ARTICLE	IF	CITATIONS
37	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	1.5	70
38	Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice. <i>PLoS ONE</i> , 2019, 14, e0221528.	1.1	7
39	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	1.9	9
40	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	0.8	13
41	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	1.0	15
42	Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. <i>Frontiers in Immunology</i> , 2019, 10, 1026.	2.2	31
43	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
44	Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. <i>Scientific Reports</i> , 2019, 9, 4530.	1.6	43
45	Response to Middleton KR et als. Yoga and SLE. <i>Complementary Therapies in Medicine</i> , 2019, 43, 311.	1.3	0
46	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 166-175.	1.0	12
47	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
48	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	2.9	55
49	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibodyâ€“Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	1.5	37
50	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€“Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	1.5	8
51	Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1550-E1559.	3.3	164
52	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 393-396.	1.0	27
53	The non-haemostatic role of platelets in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2018, 14, 195-213.	3.5	78
54	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	1.5	21

#	ARTICLE	IF	CITATIONS
55	Sharing Ongoing Care with Primary Care Physicians Opens Up Opportunity for Timelier and Earlier Care by Rheumatologists for Patients with New Inflammatory Polyarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 266-273.	1.0	3
56	CS-36â€¦Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
57	Alpha2beta1 Integrin (VLA-2) Protects Activated Human Effector T Cells From Methotrexate-Induced Apoptosis. <i>Frontiers in Immunology</i> , 2018, 9, 2269.	2.2	6
58	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	1.0	43
59	Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. <i>PLoS ONE</i> , 2018, 13, e0196117.	1.1	40
60	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , 2018, 45, 1440-1447.	1.0	12
61	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. <i>Arthritis Care and Research</i> , 2017, 69, 124-132.	1.5	16
62	Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study. <i>Clinical Rheumatology</i> , 2017, 36, 2667-2671.	1.0	30
63	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
64	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). <i>PLoS ONE</i> , 2017, 12, e0189840.	1.1	26
65	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2016, 56, kew441.	0.9	13
66	Mitochondria drive NETosis and inflammation in SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 195-196.	3.5	18
67	The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. <i>Journal of Rheumatology</i> , 2016, 43, 861-868.	1.0	13
68	Distinct Subtypes of Microparticle-containing Immune Complexes Are Associated with Disease Activity, Damage, and Carotid Intima-media Thickness in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016, 43, 2019-2025.	1.0	49
69	Calcinosis is associated with digital ischaemia in systemic sclerosisâ€”a longitudinal study. <i>Rheumatology</i> , 2016, 55, 2148-2155.	0.9	52
70	A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 218.	1.6	27
71	Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. <i>Environmental Research</i> , 2016, 146, 85-91.	3.7	94
72	Development of the Lupus Interactive Navigator as an Empowering Web-Based eHealth Tool to Facilitate Lupus Management: Users Perspectives on Usability and Acceptability. <i>JMIR Research Protocols</i> , 2016, 5, e44.	0.5	17

#	ARTICLE	IF	CITATIONS
73	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 143.	1.6	180
74	Unpacking Early Work Experiences of Young Adults With Rheumatic Disease: An Examination of Absenteeism, Job Disruptions, and Productivity Loss. <i>Arthritis Care and Research</i> , 2015, 67, 1246-1254.	1.5	42
75	Job Accommodations Availability and Utilization Among People With Lupus: An Examination of Workplace Activity Limitations and Work Context Factors. <i>Arthritis Care and Research</i> , 2015, 67, 1536-1544.	1.5	9
76	Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. <i>Arthritis Research and Therapy</i> , 2015, 17, 197.	1.6	52
77	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 449-457.	0.9	37
78	Interferon- α induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2015, 58, 100-110.	3.0	38
79	Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. <i>Environmental Research</i> , 2015, 140, 474-478.	3.7	54
80	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 128-135.	1.5	39
81	Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. <i>Joint Bone Spine</i> , 2015, 82, 373-375.	0.8	2
82	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.5	70
83	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015, 67, 582-587.	1.5	60
84	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
85	Work factors are associated with workplace activity limitations in systemic lupus erythematosus. <i>Rheumatology</i> , 2014, 53, 2044-2052.	0.9	17
86	Systemic Autoimmune Rheumatic Disease Prevalence in Canada: Updated Analyses Across 7 Provinces. <i>Journal of Rheumatology</i> , 2014, 41, 673-679.	1.0	28
87	Transitioning to Employment with a Rheumatic Disease: The Role of Independence, Overprotection, and Social Support. <i>Journal of Rheumatology</i> , 2014, 41, 2386-2394.	1.0	21
88	Rheumatoid arthritis prevalence in Quebec. <i>BMC Research Notes</i> , 2014, 7, 937.	0.6	23
89	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.5	115
90	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	1.0	28

#	ARTICLE	IF	CITATIONS
91	Toward the Development of a Lupus Interactive Navigator to Facilitate Patients and Their Health Care Providers in the Management of Lupus: Results of Web-Based Surveys. <i>JMIR Research Protocols</i> , 2014, 3, e65.	0.5	2
92	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	3.0	249
93	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
94	The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 831-841.	1.0	105
95	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.5	78
96	Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus. <i>Oncology</i> , 2013, 85, 235-240.	0.9	30
97	A Hot Spot for Systemic Lupus Erythematosus, but Not for Psoriatic Arthritis, Identified by Spatial Analysis Suggests an Interaction Between Ethnicity and Place of Residence. <i>Arthritis and Rheumatism</i> , 2013, 65, 1579-1585.	6.7	9
98	Systematic Review of Validation Studies of the Use of Administrative Data to Identify Serious Infections. <i>Arthritis Care and Research</i> , 2013, 65, 1343-1357.	1.5	62
99	Association of Smoking With Cutaneous Manifestations in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2013, 65, 1275-1280.	1.5	60
100	Longitudinal Evolution of Risk of Coronary Heart Disease in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 968-973.	1.0	18
101	Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 254-261.	1.0	34
102	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.5	143
103	Ten-year Absolute Fracture Risk and Hip Bone Strength in Canadian Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1378-1384.	1.0	20
104	Evaluation of Clinical Outcomes and Renal Vascular Pathology among Patients with Lupus. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 757-764.	2.2	51
105	Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 179-185.	1.6	124
106	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
107	Molecular Markers of Injury in Kidney Biopsy Specimens of Patients with Lupus Nephritis. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 143-151.	1.2	28
108	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. <i>Kidney International</i> , 2011, 79, 914-920.	2.6	60

#	ARTICLE	IF	CITATIONS
109	Infections in the lupus patient: perspectives on prevention. <i>Current Opinion in Rheumatology</i> , 2011, 23, 358-365.	2.0	60
110	Peripheral Neuropathy in Patients with Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 203-211.	1.6	126
111	Posterior Reversible Encephalopathy Syndrome: An Emerging Disease Manifestation in Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 353-363.	1.6	46
112	Association of autoantibodies to heat shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2011, 63, 2416-2424.	6.7	11
113	Healthcare Cost and Loss of Productivity in a Canadian Population of Patients with and without Lupus Nephritis. <i>Journal of Rheumatology</i> , 2011, 38, 658-666.	1.0	32
114	Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus. <i>Journal of Parenteral and Enteral Nutrition</i> , 2011, 35, 198-208.	1.3	29
115	Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A Reliable Index for Measuring Improvement in Disease Activity. <i>Journal of Rheumatology</i> , 2011, 38, 868-873.	1.0	27
116	Increased Expression of B Cell Activation Factor Supports the Abnormal Expansion of Transitional B Cells in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 642-651.	1.0	31
117	Thrombovascular Events Affect Quality of Life in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 1017-1019.	1.0	14
118	Medication Use in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 271-274.	1.0	12
119	Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. <i>Rheumatology</i> , 2011, 50, 799-805.	0.9	9
120	Development and initial validation of a self-assessed lupus organ damage instrument. <i>Arthritis Care and Research</i> , 2010, 62, 559-568.	1.5	40
121	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 863-868.	6.7	245
122	Clinical and Serologic Factors Associated with Lupus Pleuritis. <i>Journal of Rheumatology</i> , 2010, 37, 747-753.	1.0	28
123	Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. <i>Rheumatology</i> , 2010, 49, 2172-2180.	0.9	142
124	Altered Expression of TNF- α Signaling Pathway Proteins in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 1658-1666.	1.0	30
125	The Use of Micronutrient Supplements Is Not Associated with Better Quality of Life and Disease Activity in Canadian Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 87-90.	1.0	15
126	Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 1667-1672.	1.0	42

#	ARTICLE	IF	CITATIONS
127	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. <i>Journal of Rheumatology</i> , 2009, 36, 1200-1208.	1.0	111
128	Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 108-112.	0.6	10
129	Work disability in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 378-385.	6.7	67
130	Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2009, 41, 71-76.	9.4	448
131	Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. <i>Thrombosis and Haemostasis</i> , 2009, 101, 100-107.	1.8	25
132	Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. <i>Arthritis and Rheumatism</i> , 2008, 59, 169-175.	6.7	95
133	Steroid-sparing effects of methotrexate in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 1796-1804.	6.7	136
134	Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. <i>Nature Genetics</i> , 2008, 40, 1059-1061.	9.4	534
135	Reduced proportions of NKT cells are present in the relatives of lupus patients and are associated with autoimmunity. <i>Arthritis Research and Therapy</i> , 2008, 10, R108.	1.6	36
136	Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 654-662.	2.4	11
137	Expanded Population of Activated Antigen-Engaged Cells within the Naive B Cell Compartment of Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2008, 180, 1276-1284.	0.4	55
138	Costs of Rheumatoid Arthritis: New Estimates from the Human Capital Method and Comparison to the Willingness-to-Pay Method. <i>Medical Decision Making</i> , 2007, 27, 138-150.	1.2	46
139	The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs. <i>Arthritis and Rheumatism</i> , 2007, 57, 64-70.	6.7	58
140	Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 1270-1278.	6.7	37
141	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2211-2219.	6.7	25
142	“What do you expect? You're just getting older”: A comparison of perceived osteoarthritis-related and aging-related health experiences in middle- and older-age adults. <i>Arthritis and Rheumatism</i> , 2006, 55, 905-912.	6.7	177
143	Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. <i>Arthritis and Rheumatism</i> , 2005, 53, 67-72.	6.7	37
144	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 53, 609-612.	6.7	75

#	ARTICLE	IF	CITATIONS
145	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. <i>Quality of Life Research</i> , 2005, 14, 1333-1344.	1.5	72
146	Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1312-1319.	1.8	20
147	The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. <i>Journal of Rheumatology</i> , 2003, 30, 2385-91.	1.0	35
148	Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. <i>Thrombosis and Haemostasis</i> , 2003, 90, 108-15.	1.8	27
149	Purpura fulminans and anticardiolipin antibodies in a patient with Grave's disease. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 371-373.	0.6	14
150	Measuring Clinically Important Changes With Patient-Oriented Questionnaires. <i>Medical Care</i> , 2002, 40, 11-45-11-51.	1.1	88
151	Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 488-497.	2.4	42
152	Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. <i>Arthritis and Rheumatism</i> , 2002, 46, 3327-3330.	6.7	357
153	Counterbalancing patient demands with evidence: Results from a pan-canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. <i>Annals of Behavioral Medicine</i> , 2002, 24, 88-99.	1.7	52
154	Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001, 44, 2331-2337.	6.7	1,051
155	The use of alternative medical therapies in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 1410-1418.	6.7	60
156	Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. <i>Lupus</i> , 1999, 8, 660-670.	0.8	41
157	Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE). <i>Lupus</i> , 1999, 8, 606-611.	0.8	13
158	The role of stress in functional disability among women with systemic lupus erythematosus: A prospective study. <i>Arthritis and Rheumatism</i> , 1999, 12, 112-119.	6.7	67
159	The needs of patients with arthritis: The patient's perspective. <i>Arthritis and Rheumatism</i> , 1999, 12, 85-95.	6.7	67
160	Outcomes of total hip and knee replacement: Preoperative functional status predicts outcomes at six months after surgery. <i>Arthritis and Rheumatism</i> , 1999, 42, 1722-1728.	6.7	637
161	Quality of life in systemic lupus erythematosus patients during more and less active disease states: Differential contributors to mental and physical health. <i>Arthritis and Rheumatism</i> , 1999, 12, 401-410.	6.7	62
162	Comprehensive radiographic evaluation of diffuse idiopathic skeletal hyperostosis: Development and interrater reliability of a scoring system. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 88-96.	1.6	52

#	ARTICLE	IF	CITATIONS
163	Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 11, 23-31.	6.7	93
164	A Controlled Study of Diffuse Idiopathic Skeletal Hyperostosis Clinical Features and Functional Status. <i>Medicine (United States)</i> , 1997, 76, 104-117.	0.4	142
165	Familial antiphospholipid syndrome and HLA-DRB gene associations. <i>Arthritis and Rheumatism</i> , 1997, 40, 1907-1908.	6.7	13
166	Vasculitides associated with malignancy. <i>Current Opinion in Rheumatology</i> , 1996, 8, 30-33.	2.0	68
167	Measuring relevant change: an emerging challenge in rheumatologic clinical trials. <i>Arthritis and Rheumatism</i> , 1995, 38, 1027-1030.	6.7	90
168	Validation of a meta-analysis: The effects of fish oil in rheumatoid arthritis. <i>Journal of Clinical Epidemiology</i> , 1995, 48, 1379-1390.	2.4	183
169	Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: A new syndrome presenting with facial swelling and pericardial tamponade. <i>Arthritis and Rheumatism</i> , 1991, 34, 228-233.	6.7	41